SCHEMBL25933747

SCHEMBL25933747

CN(CC(=O)NC1CCCCC1)c1nc(-c2cc(O)ccn2)nc2c1CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
TSHR P16473 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ADORA3 P0DMS8 2/20 0.37
KMT2A Q03164 5/20 0.37
MEN1 O00255 4/20 0.37
POLB P06746 1/20 0.37
KDM4E B2RXH2 2/20 0.35
GAA P10253 1/20 0.35
MITF O75030 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
OPRK1 P41145 1/20 0.35
HTT P42858 1/20 0.35
PAX8 Q06710 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
MAPK1 P28482 1/20 0.35
AGTR1 P30556 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23975788 0.90 KMT2A (0.45) LMNATSHRSMN1; SMN2KMT2AMEN1
SCHEMBL23975860 0.90 SMN1; SMN2 (0.43) LMNASMN1; SMN2ADORA3KMT2AMEN1
SCHEMBL30118615 0.90 SMN1; SMN2 (0.43) LMNASMN1; SMN2ADORA3KMT2AMEN1
SCHEMBL23986833 0.89 ADORA3 (0.42) LMNASMN1; SMN2ADORA3KMT2AMEN1
SCHEMBL23976024 0.87 PDE10A (0.44) LMNATSHRSMN1; SMN2KMT2AMEN1
SCHEMBL30118764 0.87 ADORA3 (0.40) LMNATSHRSMN1; SMN2ADORA3KMT2A
SCHEMBL23975871 0.87 ADORA3 (0.40) LMNATSHRSMN1; SMN2ADORA3KMT2A
SCHEMBL25939854 0.85 PDE3B (0.36) LMNATSHRSMN1; SMN2ADORA3KMT2A
SCHEMBL23976225 0.84 MEN1 (0.37) ADORA3KMT2AMEN1POLBKDM4E
SCHEMBL23976757 0.84 ADORA3 (0.36) LMNATSHRSMN1; SMN2ADORA3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 LMNA 1425/4885TSHR 2368/4885SMN1; SMN2 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.